Kos Biotechnology Partners has raised $123 million (EUR 106 million) for its inaugural global life sciences fund, becoming the first life sciences-focused investment fund in Greece and the largest venture capital fund launch in the country’s history. Backed by institutional investors including the Hellenic Development Bank of Investments (HDBI), the fund will invest across biotech, pharma services, and technology-enabled life sciences companies from formation through Series C.

Skybound Venture Capital officially launches with $38 million raised from leading Greek institutional and private investors. The fund remains open to a limited number of new investors ahead of its final close.

On July 6, SEV organized a workshop on Cybersecurity in the Age of AI, bringing together business leaders, cybersecurity experts, and technology companies to discuss how organizations can leverage AI to strengthen security while addressing emerging AI-driven threats. The event featured expert insights, live demonstrations, and practical examples of AI applications in threat detection, vulnerability management, incident response, and cyber resilience.

On May 29, Athens Life Tech Park hosted Athens Life Sciences Day a flagship life sciences event of Panathēnea 2026, with nearly 270 attendees and speakers from Arsenal Capital, Biomed VC, CD3 – Centre for Drug Desing and Discovery, Pfizer CDI, Fathom Therapeutics, Flagship Pioneering, and others.